Does treatment delay for blunt cerebrovascular injury affect stroke rate?: An EAST multicenter study.


Journal

Injury
ISSN: 1879-0267
Titre abrégé: Injury
Pays: Netherlands
ID NLM: 0226040

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 02 03 2022
revised: 13 08 2022
accepted: 16 08 2022
pubmed: 10 9 2022
medline: 25 10 2022
entrez: 9 9 2022
Statut: ppublish

Résumé

The purpose of this study was to analyze injury characteristics and stroke rates between blunt cerebrovascular injury (BCVI) with delayed vs non-delayed medical therapy. We hypothesized there would be increased stroke formation with delayed medical therapy. This is a sub-analysis of a 16 center, prospective, observational trial on BCVI. Delayed medial therapy was defined as initiation >24 hours after admission. BCVI which did not receive medical therapy were excluded. Subgroups for injury presence were created using Abbreviated Injury Scale (AIS) score >0 for AIS categories. 636 BCVI were included. Median time to first medical therapy was 62 hours in the delayed group and 11 hours in the non-delayed group (p < 0.001). The injury severity score (ISS) was greater in the delayed group (24.0 vs the non-delayed group 22.0, p <  0.001) as was the median AIS head score (2.0 vs 1.0, p <  0.001). The overall stroke rate was not different between the delayed vs non-delayed groups respectively (9.7% vs 9.5%, p = 1.00). Further evaluation of carotid vs vertebral artery injury showed no difference in stroke rate, 13.6% and 13.2%, p = 1.00 vs 7.3% and 6.5%, p = 0.84. Additionally, within all AIS categories there was no difference in stroke rate between delayed and non-delayed medical therapy (all N.S.), with AIS head >0 13.8% vs 9.2%, p = 0.20 and AIS spine >0 11.0% vs 9.3%, p = 0.63 respectively. Modern BCVI therapy is administered early. BCVI with delayed therapy were more severely injured. However, a higher stroke rate was not seen with delayed therapy, even for BCVI with head or spine injuries. This data suggests with competing injuries or other clinical concerns there is not an increased stroke rate with necessary delays of medical treatment for BCVI.

Sections du résumé

BACKGROUND BACKGROUND
The purpose of this study was to analyze injury characteristics and stroke rates between blunt cerebrovascular injury (BCVI) with delayed vs non-delayed medical therapy. We hypothesized there would be increased stroke formation with delayed medical therapy.
METHODS METHODS
This is a sub-analysis of a 16 center, prospective, observational trial on BCVI. Delayed medial therapy was defined as initiation >24 hours after admission. BCVI which did not receive medical therapy were excluded. Subgroups for injury presence were created using Abbreviated Injury Scale (AIS) score >0 for AIS categories.
RESULTS RESULTS
636 BCVI were included. Median time to first medical therapy was 62 hours in the delayed group and 11 hours in the non-delayed group (p < 0.001). The injury severity score (ISS) was greater in the delayed group (24.0 vs the non-delayed group 22.0, p <  0.001) as was the median AIS head score (2.0 vs 1.0, p <  0.001). The overall stroke rate was not different between the delayed vs non-delayed groups respectively (9.7% vs 9.5%, p = 1.00). Further evaluation of carotid vs vertebral artery injury showed no difference in stroke rate, 13.6% and 13.2%, p = 1.00 vs 7.3% and 6.5%, p = 0.84. Additionally, within all AIS categories there was no difference in stroke rate between delayed and non-delayed medical therapy (all N.S.), with AIS head >0 13.8% vs 9.2%, p = 0.20 and AIS spine >0 11.0% vs 9.3%, p = 0.63 respectively.
CONCLUSIONS CONCLUSIONS
Modern BCVI therapy is administered early. BCVI with delayed therapy were more severely injured. However, a higher stroke rate was not seen with delayed therapy, even for BCVI with head or spine injuries. This data suggests with competing injuries or other clinical concerns there is not an increased stroke rate with necessary delays of medical treatment for BCVI.

Identifiants

pubmed: 36085175
pii: S0020-1383(22)00603-9
doi: 10.1016/j.injury.2022.08.043
pii:
doi:

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3702-3708

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflict of interest None.

Auteurs

Rachel D Appelbaum (RD)

Vanderbilt University Medical Center. Electronic address: rachel.appelbaum@vumc.org.

Emily Esposito (E)

R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine.

Julie Dunn (J)

University of Colorado Health.

Linda B Zier (LB)

University of Colorado Health.

Sigrid Burruss (S)

Loma Linda University Health.

Paul P Kim (PP)

Loma Linda University Health.

Jeffry Nahmias (J)

University of California, Irvine.

Areg Grigorian (A)

University of Southern California.

Laura Harmon (L)

University of Colorado Anschutz.

Anna K Gergen (AK)

University of Colorado Anschutz.

Matthew Chatoor (M)

Legacy Emanuel Medical Center.

Rishi Rattan (R)

University of Miami Health System.

Andrew J Young (AJ)

The Ohio State University Wexner Medical Center.

Jose L Pascual (JL)

University of Pennsylvania.

Jason Murry (J)

UT Health East Texas.

Adrian W Ong (AW)

Tower Health.

Alison Muller (A)

Tower Health.

Rovinder S Sandhu (RS)

Lehigh Valley Health Network.

Nikolay Bugaev (N)

Tufts Medical Center.

Antony Tatar (A)

University of Massachusetts Medical School.

Khaled Zreik (K)

Sanford Health.

Mark J Lieser (MJ)

Envision Health.

Deborah M Stein (DM)

R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine.

Thomas M Scalea (TM)

R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine.

Margaret H Lauerman (MH)

R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH